[Does chemotherapy and radiotherapy influence the level of oxidative stress in children with malignant bone tumours?].
Reactive oxygen species may play a role in initiation, promotion and progression of malignancies. Radiotherapy of neoplasms is a strong egzogenous source of reactive oxygen species. Chemotherapy with anthracyclines is also a source of reactive oxygen species. Protein carbonyl groups are a well known marker of protein peroxidation. THE AIM of the study was to analyse the carbonyl groups in children with malignant bone tumours, who underwent chemotherapy and radiotherapy or only chemotherapy with anthracyclines.


METHODS
A group of 55 children aged from 6 to 18 years with malignant bone tumour was examined; osteosarcoma (n=35) and Ewing sarcoma (n=20). There were 30 children examined before the treatment was started, 19 with osteosarcoma after chemotherapy with anthracyclines (program EORTC) and 13 with Ewing sarcoma after chemotherapy with anthracyclines and radiotherapy with doses 45-55 Gy (program EICESS 92). The analysis of protein carbonyls' content was evaluated by colorimetric method with the use of 2,4 dinitrophenylhydrazine.


RESULTS
It was found that plasma carbonyl groups in children before the treatment was 1.36 +/- 0.70 nmol/mg of protein (osteosarcoma--1.42 +/- 0.70, Ewing sarcoma--1.25 +/- 0.78). After chemotherapy, in osteosarcoma the carbonyl content diminished to 1.11 +/- 0.49, and after chemotherapy with radiotherapy, in Ewing sarcoma it grew to 1.39 +/- 0.55. The carbonyl level in the whole treated group (chemotherapy and radiotherapy) was 1.25 +/- 0.53. None of the differences reached statistical significance.


CONCLUSIONS
In children with malignant bone tumours chemotherapy and radiotherapy did not influence the level of oxidative stress.
Popadiuk
Stefan
S
Klinika Pediatrii, Gastroenterologii i Onkologii Dzieciecej, Akademia Medyczna, ul. Nowe Ogrody 1-6, 80-803 Gdańsk, Poland. step@amg.gda.pl
Renke
Joanna
J
Woźniak
Michał
M
Korzon
Maria
M
D000293:Adolescent; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D018384:Oxidative Stress / Q000187:drug effects* / Q000528:radiation effects*; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D016896:Treatment Outcome